The promise of precision psychiatry has never been more tangible. New developments in neuromodulation, including MRI-guided TMS and accelerated theta-burst protocols, are moving mental health care beyond one-size-fits-all treatment and toward approaches tailored to individual brain biology. At the same time, telehealth has fundamentally restructured how psychiatric care is accessed and delivered. The question worth asking now: How much of precision interventional psychiatry can actually happen remotely, and where does the model hit a wall? The answer is potentially more nuanced than the conventional framing suggests.
The false binary between telehealth and interventional care
There is a persistent assumption in discussions about telehealth that virtual care and advanced interventional psychiatry occupy separate lanes. Telehealth handles the straightforward stuff, such as medication management, therapy, and follow-up. Interventional care, with its brain stimulation technologies and controlled clinical environments, stays in the office. That framing is increasingly outdated. Interventional psychiatry is not a monolith. Some parts of it are a natural fit for telemedicine. Some parts aren’t. The distinction matters. Conflating the two does a disservice to both.
What telehealth cannot do, at least with current technology, is administer a TMS treatment or deliver ketamine infusion. These interventions require physical presence, trained staff, calibrated equipment, and real-time clinical oversight. That constraint is real and should not be minimized. But it represents only one step in a much longer clinical process, and it may be the only step that genuinely requires an in-person visit. Everything else? Telehealth can handle it, and in many cases, handle it well.
Where remote care adds clinical value
The interventional psychiatry workflow involves far more than the treatment sessions themselves. It begins with identification and determining whether a patient is an appropriate candidate. This is where telehealth has been underutilized and where the opportunity is significant. A thorough psychiatric evaluation conducted via telehealth can gather the structured clinical data needed to guide treatment selection: symptom history, prior treatment trials, comorbidities, medication burden, functional impairment, and patient goals. Validated instruments — PHQ-9, GAD-7, Columbia Suicide Severity Rating Scale — can be administered remotely. Clinician-to-patient rapport, which matters enormously in discussions of invasive or stigmatized treatments, can be built over video before a patient ever sets foot in a clinic.
One of the biggest barriers to interventional psychiatry is patient hesitation. Many patients who might benefit from TMS or esketamine arrive at a referral carrying misconceptions, anxiety, or shame. A skilled psychiatrist conducting a thorough remote evaluation is well-positioned to address those concerns, explain the evidence base, calibrate expectations, and build the trust needed for a patient to follow through on treatment. In this way, telehealth functions as a clinical bridge.
The hybrid model in practice
A practical framework emerging from clinical experience looks something like this: Telehealth handles the evaluation, psychoeducation, candidate screening, and follow-up. The clinic handles treatment administration. In some cases, the treating psychiatrist or therapist can participate in TMS sessions remotely by joining via video to provide real-time clinical guidance while a trained technician manages the device.
Consider how motor threshold calibration works in TMS. It is the process of determining the precise stimulation strength needed to reach a patient’s cortex. A clinician can guide this entirely via video, watching as a technician slowly increases stimulation intensity over the area of the brain that controls hand movement until a visible twitch confirms that the stimulus is penetrating the skull and reaching the cortex. The patient sees the clinician on a screen. The tech serves as the clinician’s eyes, ears, and hands. The clinical judgment driving the process is happening remotely.
This is already being practiced in settings where geography, staffing constraints, or patient preference make full in-person care impractical. A patient in a rural area, for example, might drive to a regional TMS center three times per week while maintaining all clinical touchpoints with their psychiatrist remotely. The quality of that longitudinal relationship, including the consistency of follow-up, the responsiveness to symptom changes, and the integration of therapy alongside neuromodulation, does not require co-location.
Looking further ahead, emerging psychedelic-assisted therapies, including psilocybin and MDMA-assisted treatment, may follow a similar hybrid logic. These protocols require the presence of a therapist and nursing staff for safety, but the prescribing physician’s role may be manageable via a brief video visit: reviewing the plan, completing informed consent, advising the patient, and remaining available for consultation. The physical administration is handled on-site. The clinical oversight is distributed.
Outcome tracking is another domain where telehealth-enabled remote measurement adds real value. Wearables, app-based mood monitoring, and structured check-ins can generate longitudinal symptom data between sessions that would otherwise be invisible to a provider seeing a patient only at weekly in-person appointments. In a field where treatment response can shift meaningfully week to week, that continuous data stream improves clinical decision-making.
Where the limits are real
Precision neuromodulation is advancing rapidly. Techniques such as fMRI-guided targeting, EEG-informed stimulation, and emerging closed-loop TMS systems that adapt parameters in real time based on brain state monitoring are pushing the field toward genuinely individualized treatment. These approaches require imaging infrastructure, specialized equipment, and trained operators working in controlled environments.
There is also a safety dimension worth acknowledging. Patients who are acutely suicidal, medically unstable, or presenting with psychiatric complexity that warrants close physical monitoring require in-person care. Telehealth is not equipped to manage clinical emergencies, and a responsible hybrid model has to account for those situations with clear protocols and escalation pathways.
The regulatory environment adds another layer. Controlled substance prescribing via telemedicine, which is relevant for practitioners using ketamine or other rapidly acting interventions, has operated under extended pandemic-era waivers that are now sunsetting. The DEA’s finalization of telehealth prescribing rules will shape how hybrid models function, and practices integrating interventional psychiatry with telehealth will need to track that evolving landscape carefully.
The practical implications for health system stakeholders
The in-person footprint required for interventional psychiatry does not need to be as large or as expensive as traditional models assume. A smaller number of well-equipped treatment facilities, combined with robust telehealth infrastructure for evaluation, monitoring, and follow-up, could dramatically expand access to precision interventional care without proportionally scaling physical overhead.
This has meaningful implications for health equity. Patients in underserved areas face not just geographic barriers to TMS and related treatments, but informational ones. Many have never been told these options exist, let alone had a clinician take time to explain them in plain language. A well-structured telehealth evaluation is a low-friction point of entry into that conversation and potentially the first step toward a treatment that changes the trajectory of a patient’s illness.
But expanding access responsibly means resisting the temptation to let the convenience of telehealth drive clinical decision-making. The evidence should guide the model, not the other way around. The field has an opportunity to build something genuinely better. That requires the same rigor we apply to any clinical intervention. The complexity of precision interventional psychiatry does not make it incompatible with telehealth. It makes thoughtful integration of the two more important than ever.
Photo: Alisa Zahoruiko, Getty Images
Mottsin Thomas, MD, is a board-certified psychiatrist and the founder of bonmente, a California-based comprehensive telepsychiatry practice. Committed to clinical excellence, Dr. Thomas rigorously evaluates emerging innovations in psychiatry to ensure that new therapies and technologies provide patients meaningful, measurable improvements in outcomes.
This post appears through the MedCity Influencers program. Anyone can publish their perspective on business and innovation in healthcare on MedCity News through MedCity Influencers. Click here to find out how.
